In this study, we have shown that iNOS is a central downstream effector of cachexia, both in sepsis and cancer models, and that its inhibition with the clinically tested drug GW274150 can successfully ameliorate cancer‐associated cachexia. Here, NOS2 is linked to Cachexia.